Genomics, metabolomics and proteomics are revolutionizing healthcare through individualized medicine. LCMS is used to define these molecules and is assisting with tailoring therapy based on each patients metabolic profile.

We unveiled the Human Genome in one minute compared to how much time we will need to figure out the individual metabolic composition. This is a tall order and Soft Landing Labs is planning on playing a significant role in this transformation.

We are particularly interested in Phase I and II metabolism of Xenobiotics and how to best utilize LCMS to match the right medication to the individual patient. Genetic polymorphism that we are discovering every day will make such selection possible.

Pharmacogenetics is in its infancy and far from being commercialized or used to its limit. Healthcare reform has provisions that encourage and promote research and development in this field.